Trending Now: New Research on Aeropostale, Impax, Facebook, TripAdvisor and BIND Therapeutics

NEW YORK, January 9, 2015 /PRNewswire/ --

Moments ago, Analysts Review released new research updates concerning several important developing situations including Aeropostale (NYSE: ARO), Impax (NASDAQ: IPXL), Facebook (NASDAQ: FB), TripAdvisor (NASDAQ: TRIP), and BIND Therapeutics (NASDAQ: BIND). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.

To access our full PDF reports on a complementary basis, please visit the links below.

--

Today's update concerns the following companies:

============

Full PDF Download Links (you may have to copy and paste the following links into your browser):

ARO Research Report: ( http://get.analystsreview.com/pdf/?c=Aeropostale&d=09-Jan-2015&s=ARO ),

IPXL Research Report: ( http://get.analystsreview.com/pdf/?c=Impax&d=09-Jan-2015&s=IPXL ),

FB Research Report: ( http://get.analystsreview.com/pdf/?c=Facebook&d=09-Jan-2015&s=FB ),

TRIP Research Report: ( http://get.analystsreview.com/pdf/?c=TripAdvisor&d=09-Jan-2015&s=TRIP ),

BIND Research Report: ( http://get.analystsreview.com/pdf/?c=BIND%20Therapeutics&d=09-Jan-2015&s=BIND ).

============

--

Analyst Update: Performance Updates,FDA Approval, Acquisitions, and Study Results

Reviewed by: Rohit Tuli, CFA®  

The U.S. markets rose for the second consecutive session on Thursday, with S&P 500 index erasing its 2015 declines, as steadying crude oil prices coupled with dovish comments from a leading U.S. Federal Reserve official further boosted the appetite for risky assets. Investors also cheered the latest U.S. unemployment data which showed that jobless claims fell last week, bolstering hopes of faster growth in the world's biggest economy this year. The Dow Jones Industrial Average also reversed this year's declines and ended higher by 1.84% at 17,907.87 on Thursday. S&P 500 jumped 1.79% to close at 2,062.14, and the Nasdaq Composite gained 1.84% to finish at 4,736.19. European shares also rose on Thursday amidst rising prospect of new stimulus from the European Central Bank. Asian equity markets were also mostly higher on Thursday, driven by strong U.S. data and hopes of fresh stimulus from ECB.

Shares of the U.S.-based specialty retailer Aeropostale, Inc. (Aeropostale) rallied nearly 24% on Thursday after the Company said that it achieved higher margins than originally expected for the holiday season, while same-store sales decline slowed down. The Company also stated that its fourth quarter fiscal 2014 loss is expected to be smaller than previously forecasted. To read more about the Company's holiday season performance, please visit our exclusive research report.

Impax Laboratories, Inc. (Impax) announced that the U.S. Food and Drug Administration (FDA) has approved its RYTARY drug for the treatment of Parkinson's disease, sending its shares to a new 52-week high. Moody's Investors Service sees FDA approval for RYTARY as credit positive for Impax. To know more about Impax's first internally developed branded drug and its potential impact on the Company's topline, please visit our research report.

U.S.-based social networking giant Facebook, Inc. (Facebook) has acquired QuickFire Networks, a startup firm that helps reduce the bandwidth needed to view video online without degrading the video quality. The latest acquisition underscores Facebook's increasing focus on video as the Company continues to average more than one billion video views every day. Read more about Facebook's latest acquisition in our research report.

TripAdvisor, Inc. (TripAdvisor) has agreed to acquire Netherlands-based online restaurant review and booking site Iens. SeatMe, which merged with Iens in 2012 and allows users to book tables, will also be acquired by TripAdvisor. Know more about TripAdvisor's latest acquisition in our research report.

Shares of BIND Therapeutics, Inc. (BIND Therapeutics) jumped over 37% on Thursday on significantly higher than normal volume after the Company announced update on BIND-014 and outlook for this year. Know more about BIND Therapeutics' ongoing Phase 2 trial and the Company's plans ahead in our exclusive research.

--

About Analysts Review  

At Analysts Review, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

Analysts Review was designed for investors. By providing the best information available, we have set ourselves apart as one of the premier online investor communities.

--

Editor Note: This is not company news. We are an independent source and our views do not reflect the companies mentioned.

Compliance Procedure: Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA®. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

Further Resources: For more information about this release including editorial notes, compliance procedures and legal disclosures, please visit: http://www.analystsreview.com/editors

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED